Valuation: Evogene Ltd.

Market Cap 6.32M 0 5.62M 5.25M 4.78M 9.02M 608M 9.1M 63.47M 24.6M 311M 23.75M 23.23M 998M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.32M 0 5.62M 5.25M 4.78M 9.02M 608M 9.1M 63.47M 24.6M 311M 23.75M 23.23M 998M EV / Sales 2026 *
4.4x
EV / Sales 2027 * 2.43x
Free-Float
72.14%
Yield 2026 *
-
Yield 2027 * -
1 day-3.59%
1 week-9.46%
Current month-3.59%
1 month-25.02%
3 months-5.87%
6 months-51.93%
Current year-58.92%
1 week 113.3
Extreme 113.3
164.6
1 month 113.3
Extreme 113.3
167.9
Current year 113.3
Extreme 113.3
410
1 year 113.3
Extreme 113.3
478.7
3 years 113.3
Extreme 113.3
3,700
5 years 113.3
Extreme 113.3
9,289
10 years 113.3
Extreme 113.3
33,500
Manager TitleAgeSince
Chief Executive Officer 60 01/12/2004
Corporate Officer/Principal - -
Corporate Officer/Principal - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 -
Director/Board Member 77 03/06/2010
Chairman 60 01/06/2021
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 A Free

Chairman

10,000 0.0754%
9/4/26 A Other

Director

2,500 0.0189%
9/4/26 A Free

Director

2,500 0.0189%
Change 5-day change 1-year change 3-year change Capi.($)
-3.59%-9.46%-68.77%-94.68% 6.38M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.56%-1.48%+40.49%+106.22% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales 1.44M 0 1.28M 1.19M 1.09M 2.05M 138M 2.07M 14.41M 5.58M 70.57M 5.39M 5.27M 226M 2.6M 0 2.31M 2.16M 1.97M 3.71M 250M 3.74M 26.09M 10.11M 128M 9.76M 9.55M 410M
Net income -12.17M -0 -10.81M -10.09M -9.2M -17.35M -1.17B -17.51M -122M -47.32M -598M -45.69M -44.7M -1.92B -10.2M -0 -9.06M -8.46M -7.71M -14.54M -981M -14.68M -102M -39.67M -501M -38.3M -37.46M -1.61B
Net Debt - -
Logo Evogene Ltd.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Employees
52
Date Price Change Volume
01/10/26 ILA 123.50 -3.59% 93,252
30/09/26 ILA 128.10 +13.06% 580,165
29/09/26 ILA 113.30 -17.72% 311,774
28/09/26 ILA 137.70 +0.95% 25,699

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVGN Stock